S&P 500   4,299.70
DOW   33,666.34
QQQ   358.01
Can Undervalued Healthcare Stocks Add Yield To Your Portfolio?
U.S. drive to onshore battery supply chains could create big winners in lithium (Ad)
Stock market today: European shares gain and Asian shares are mixed, with Chinese markets on holiday
Nursing Home REITs: The Surprise Heroes of High Yield Investing
U.S. drive to onshore battery supply chains could create big winners in lithium (Ad)
Energy Stocks Shine as High Oil Prices Boost Dividend Yields
Billionaire Ryan Cohen takes over as CEO at GameStop, adding to chairman role
U.S. drive to onshore battery supply chains could create big winners in lithium (Ad)
Liverpool owner FSG announces minority investment by New York equity firm
3 Reasons Micron is a Buy on Market Weakness
S&P 500   4,299.70
DOW   33,666.34
QQQ   358.01
Can Undervalued Healthcare Stocks Add Yield To Your Portfolio?
U.S. drive to onshore battery supply chains could create big winners in lithium (Ad)
Stock market today: European shares gain and Asian shares are mixed, with Chinese markets on holiday
Nursing Home REITs: The Surprise Heroes of High Yield Investing
U.S. drive to onshore battery supply chains could create big winners in lithium (Ad)
Energy Stocks Shine as High Oil Prices Boost Dividend Yields
Billionaire Ryan Cohen takes over as CEO at GameStop, adding to chairman role
U.S. drive to onshore battery supply chains could create big winners in lithium (Ad)
Liverpool owner FSG announces minority investment by New York equity firm
3 Reasons Micron is a Buy on Market Weakness
S&P 500   4,299.70
DOW   33,666.34
QQQ   358.01
Can Undervalued Healthcare Stocks Add Yield To Your Portfolio?
U.S. drive to onshore battery supply chains could create big winners in lithium (Ad)
Stock market today: European shares gain and Asian shares are mixed, with Chinese markets on holiday
Nursing Home REITs: The Surprise Heroes of High Yield Investing
U.S. drive to onshore battery supply chains could create big winners in lithium (Ad)
Energy Stocks Shine as High Oil Prices Boost Dividend Yields
Billionaire Ryan Cohen takes over as CEO at GameStop, adding to chairman role
U.S. drive to onshore battery supply chains could create big winners in lithium (Ad)
Liverpool owner FSG announces minority investment by New York equity firm
3 Reasons Micron is a Buy on Market Weakness
S&P 500   4,299.70
DOW   33,666.34
QQQ   358.01
Can Undervalued Healthcare Stocks Add Yield To Your Portfolio?
U.S. drive to onshore battery supply chains could create big winners in lithium (Ad)
Stock market today: European shares gain and Asian shares are mixed, with Chinese markets on holiday
Nursing Home REITs: The Surprise Heroes of High Yield Investing
U.S. drive to onshore battery supply chains could create big winners in lithium (Ad)
Energy Stocks Shine as High Oil Prices Boost Dividend Yields
Billionaire Ryan Cohen takes over as CEO at GameStop, adding to chairman role
U.S. drive to onshore battery supply chains could create big winners in lithium (Ad)
Liverpool owner FSG announces minority investment by New York equity firm
3 Reasons Micron is a Buy on Market Weakness

Fate Therapeutics (FATE) Stock Forecast, Price & News

$2.18
+0.08 (+3.81%)
(As of 09/28/2023 ET)
Compare
Today's Range
$2.03
$2.19
50-Day Range
$2.02
$4.46
52-Week Range
$1.99
$23.96
Volume
1.54 million shs
Average Volume
3.27 million shs
Market Capitalization
$214.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.96

Fate Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.15 Rating Score
Upside/​Downside
494.6% Upside
$12.96 Price Target
Short Interest
Bearish
26.17% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.70
Upright™ Environmental Score
News Sentiment
1.37mentions of Fate Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$59,353 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.91) to ($2.13) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.46 out of 5 stars

Medical Sector

195th out of 969 stocks

Biological Products, Except Diagnostic Industry

26th out of 161 stocks


FATE stock logo

About Fate Therapeutics (NASDAQ:FATE) Stock

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

FATE Price History

FATE Stock News Headlines

Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
Fate Therapeutics: Not Now, Maybe Never?
The Latest Analyst Ratings for Fate Therapeutics
Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
FATE Q2 Earnings Beat on Lower Expenses, Revenues Miss
See More Headlines
Receive FATE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fate Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FATE Company Calendar

Last Earnings
8/08/2023
Today
9/29/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:FATE
Fax
N/A
Employees
551
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$12.96
High Stock Price Forecast
$65.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+494.6%
Consensus Rating
Hold
Rating Score (0-4)
2.15
Research Coverage
20 Analysts

Profitability

Net Income
$-281,720,000.00
Net Margins
-177.41%
Pretax Margin
-177.41%

Debt

Sales & Book Value

Annual Sales
$96.30 million
Book Value
$4.98 per share

Miscellaneous

Free Float
93,594,000
Market Cap
$214.86 million
Optionable
Optionable
Beta
1.47
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. J. Scott WolchkoMr. J. Scott Wolchko (Age 53)
    Founder, CEO, Pres & Director
    Comp: $645k
  • Mr. Edward J. Dulac IIIMr. Edward J. Dulac III (Age 47)
    Chief Financial Officer
    Comp: $455k
  • Ms. Cindy R. TahlMs. Cindy R. Tahl (Age 50)
    Gen. Counsel & Corp. Sec.
    Comp: $455k
  • Dr. Bahram Valamehr Ph.D. (Age 46)
    Chief R&D Officer
    Comp: $455k
  • Mr. Jim Beitel M.B.A.
    Sr. VP of Corp. Devel.
  • Dr. Jerome Bressi Ph.D.
    Sr. VP of Regulatory & Quality













FATE Stock - Frequently Asked Questions

Should I buy or sell Fate Therapeutics stock right now?

20 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last twelve months. There are currently 2 sell ratings, 13 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" FATE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FATE, but not buy additional shares or sell existing shares.
View FATE analyst ratings
or view top-rated stocks.

What is Fate Therapeutics' stock price forecast for 2023?

20 brokerages have issued 1 year price objectives for Fate Therapeutics' stock. Their FATE share price forecasts range from $5.00 to $65.00. On average, they predict the company's share price to reach $12.96 in the next year. This suggests a possible upside of 494.6% from the stock's current price.
View analysts price targets for FATE
or view top-rated stocks among Wall Street analysts.

How have FATE shares performed in 2023?

Fate Therapeutics' stock was trading at $10.09 at the start of the year. Since then, FATE stock has decreased by 78.4% and is now trading at $2.18.
View the best growth stocks for 2023 here
.

Are investors shorting Fate Therapeutics?

Fate Therapeutics saw a decrease in short interest in September. As of September 15th, there was short interest totaling 24,290,000 shares, a decrease of 12.1% from the August 31st total of 27,640,000 shares. Based on an average daily volume of 2,280,000 shares, the days-to-cover ratio is presently 10.7 days. Currently, 26.2% of the shares of the stock are sold short.
View Fate Therapeutics' Short Interest
.

When is Fate Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our FATE earnings forecast
.

How were Fate Therapeutics' earnings last quarter?

Fate Therapeutics, Inc. (NASDAQ:FATE) issued its quarterly earnings results on Tuesday, August, 8th. The biopharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.58) by $0.04. The biopharmaceutical company earned $0.93 million during the quarter, compared to the consensus estimate of $5.41 million. Fate Therapeutics had a negative trailing twelve-month return on equity of 44.14% and a negative net margin of 177.41%. Fate Therapeutics's quarterly revenue was down 95.0% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.79) EPS.

What ETF holds Fate Therapeutics' stock ?

iShares Genomics Immunology and Healthcare ETF holds 348,530 shares of FATE stock, representing 0.86% of its portfolio.

What is Scott Wolchko's approval rating as Fate Therapeutics' CEO?

2 employees have rated Fate Therapeutics Chief Executive Officer Scott Wolchko on Glassdoor.com. Scott Wolchko has an approval rating of 100% among the company's employees. This puts Scott Wolchko in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Fate Therapeutics own?
What is Fate Therapeutics' stock symbol?

Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE."

How do I buy shares of Fate Therapeutics?

Shares of FATE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Fate Therapeutics' stock price today?

One share of FATE stock can currently be purchased for approximately $2.18.

How much money does Fate Therapeutics make?

Fate Therapeutics (NASDAQ:FATE) has a market capitalization of $214.86 million and generates $96.30 million in revenue each year. The biopharmaceutical company earns $-281,720,000.00 in net income (profit) each year or ($2.17) on an earnings per share basis.

How many employees does Fate Therapeutics have?

The company employs 551 workers across the globe.

How can I contact Fate Therapeutics?

Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.fatetherapeutics.com. The biopharmaceutical company can be reached via phone at (858) 875-1800 or via email at christina@sternir.com.

This page (NASDAQ:FATE) was last updated on 9/29/2023 by MarketBeat.com Staff

My Account -